Key result
Solid organ transplant recipients had a significantly higher age-adjusted HEV IgG seroprevalence compared to non-transplant hospitalized controls (35.3% vs 27.7%; p=0.001).
Why the study?
HEV causes morbidity in solid organ transplant recipients, but the total burden of hepatitis E, including subclinical infections and rat HEV prevalence in this group, is not well defined.
Is the prevalence of HEV and rHEV infection higher in solid organ transplant recipients compared to non-transplant controls?
Cross-Sectional (n=1,336)
No
Is the prevalence of HEV and rHEV infection higher in solid organ transplant recipients compared to non-transplant controls?
Absolute Event Rate: 35.3% vs 27.7%
p-value: p=0.001
Solid organ transplant recipients have a significantly higher burden of both conventional and rat hepatitis E virus infections compared to non-transplant patients.
Higher HEV seroprevalence and subclinical infections in SOT recipients may warrant targeted screening; leaves open whether routine testing improves outcomes in transplant populations.
BACKGROUND: HEV is an important cause of morbidity in solid organ transplant (SOT) recipients. However, the total burden of hepatitis E, including subclinical infections in this group, is not well defined. We compared hepatitis E exposures in SOT recipients to non-transplant controls. We also examined the prevalence of rat HEV (rHEV), an emerging hepatitis agent, in this population. METHODS: This study was conducted in the main SOT center in Hong Kong. Quantitative HEV IgG, RT-PCR, IgM, and IgG avidity assays were used to measure conventional HEV and rHEV exposures in 669 SOT recipients and 667 non-transplant hospitalized controls. Follow-up samples from a subset of SOT recipients were assessed to measure longitudinal HEV exposures. RESULTS: Age-adjusted HEV IgG seroprevalence in SOT recipients (236/669; 35.3%) was significantly higher than non-transplant controls (185/667; 27.7%; p=0.001). Across baseline and follow-up samples, 25 (3.7%) SOT recipients had viremia (n=3) or serological evidence (n=22) of recent hepatitis E. The latter had IgM positivity (n=5), IgG seroconversion (n=16), or a 5-fold increase in longitudinal HEV IgG concentrations (n=1). Chronic hepatitis occurred in all 3 viremic individuals, while transient hepatitis was observed in 10/22 (45.4%) SOT recipients with serological evidence of recent hepatitis E. rHEV IgG levels were similar between SOT recipients and controls (p=0.424), but 2 viremic infections in the SOT group were due to rHEV and both turned chronic. CONCLUSIONS: SOT recipients have higher hepatitis E seroprevalence than the non-transplant population. Increased exposure is driven by viremic infections and a significant burden of subclinical infections in Hong Kong. rHEV is an important cause of chronic hepatitis E in SOT recipients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted a cross-sectional in Hepatitis E infection (n=1,336). Solid organ transplant vs. Non-transplant hospitalized controls was evaluated on Age-adjusted HEV IgG seroprevalence (p=0.001). Solid organ transplant recipients had a significantly higher age-adjusted HEV IgG seroprevalence compared to non-transplant hospitalized controls (35.3% vs 27.7%; p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: